This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Immunocore’s 8K filing here.
Immunocore Company Profile
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
See Also
- Five stocks we like better than Immunocore
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- What Are Dividends? Buy the Best Dividend Stocks
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Roth IRA Calculator: Calculate Your Potential Returns
- The Top 5 Performing S&P 500 Stocks YTD in 2024
